10 likes | 102 Views
This study evaluates the antitumor activity on target lesions in a group of 34 participants, showing a 65% overall response rate with complete, partial, stable, and progressive responses. The response rate post-crizotinib is 61%, and all treatment-naive patients showed a positive response. Presented at ESMO 2013, the results are based on the study by Camidge DR et al. (abstract 3401) and provide valuable insights into treatment outcomes.
E N D
CBNPC ALK+, activité antitumorale sur les lésions cibles (n = 34) Meilleure réponse globale Réponse complète Progression Stabilité Réponse partielle Taux de réponse : 65 % (22/34) [IC95 : 47-80] Post-crizotinib : 61 % (19/31) [incl. 1 criz intolérant] Naïf d’ITK : 100 % (3/3) [Incl. 1 CR] 40 20 0 -20 Variation des lésions cibles (%) -40 -60 -80 -100 • ESMO 2013 – D’après Camidge DR et al., abstr. 3401, actualisé